While Apellis Pharmaceuticals Inc has underperformed by -2.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, APLS fell by -21.28%, with highs and lows ranging from $35.72 to $16.10, whereas the simple moving average jumped by 7.14% in the last 200 days.
On September 26, 2025, Goldman Downgraded Apellis Pharmaceuticals Inc (NASDAQ: APLS) to Sell. A report published by Raymond James on May 09, 2025, Downgraded its rating to ‘Outperform’ for APLS. BofA Securities also Downgraded APLS shares as ‘Neutral’, setting a target price of $23 on the company’s shares in a report dated May 09, 2025. Cantor Fitzgerald Initiated an Overweight rating on April 29, 2025, and assigned a price target of $44. Goldman December 17, 2024d its ‘Buy’ rating to ‘Neutral’ for APLS, as published in its report on December 17, 2024. Morgan Stanley’s report from November 21, 2024 suggests a price prediction of $31 for APLS shares, giving the stock a ‘Equal-Weight’ rating. RBC Capital Mkts also rated the stock as ‘Sector Perform’.
Analysis of Apellis Pharmaceuticals Inc (APLS)
Further, the quarter-over-quarter decrease in sales is -10.61%, showing a negative trend in the upcoming months.
In order to gain a clear picture of Apellis Pharmaceuticals Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -108.49% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.16, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 2.46M can be a very valuable indicator of volatility for APLS stock. On a monthly basis, the volatility of the stock is set at 3.97%, whereas on a weekly basis, it is put at 4.96%, with a gain of 5.55% over the past seven days. Furthermore, long-term investors anticipate a median target price of $37.44, showing growth from the present price of $25.12, which can serve as yet another indication of whether APLS is worth investing in or should be passed over.
How Do You Analyze Apellis Pharmaceuticals Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.37%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 101.13% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
